The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia.
Mehdi GhasemiMufide OkaySeyhan TurkRonak NaeemaeeEbru GuverUmit Yavuz MalkanSalih AksuNilgun SayinalpIbrahim C HaznedarogluPublished in: Journal of the renin-angiotensin-aldosterone system : JRAAS (2019)
The combined treatment of the AML cell lines with losartan and doxorubicin resulted in an increase in sensitivity of some of the cell lines. Those leukaemic cells are modulated via the induction of apoptosis, whereas the other cells resistant to the drug treatment are closely related to tumour angiogenesis indicating that RAS-AT1R seems to be differently expressed in different leukaemic blast cells and tumour microenvironments. Pharmaco-biological actions of RAS inhibitors may be different in distinct leukaemic cells based on the pathological behaviour of AML genomic subtypes.
Keyphrases
- cell cycle arrest
- induced apoptosis
- endoplasmic reticulum stress
- cell death
- acute myeloid leukemia
- oxidative stress
- signaling pathway
- pi k akt
- gene expression
- bone marrow
- angiotensin ii
- drug induced
- dna methylation
- immune response
- intensive care unit
- acute lymphoblastic leukemia
- combination therapy
- vascular endothelial growth factor
- extracorporeal membrane oxygenation